about
Recurrent Gastrointestinal Hemorrhage in Treatment with Dasatinib in a Patient Showing SMAD4 Mutation with Acute Lymphoblastic Leukemia Philadelphia Positive and Juvenile Polyposis Hereditary Hemorrhagic Telangiectasia Syndrome.Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up.Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapy.FOXP1 and TP63 involvement in the progression of myelodysplastic syndrome with 5q- and additional cytogenetic abnormalitiesThe response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phaseExpression of CD86 in acute myelogenous leukemia is a marker of dendritic/monocytic lineage.Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma.BCR-ABL1-associated reduction of beta catenin antagonist Chibby1 in chronic myeloid leukemiaThe cytogenetic response as a surrogate marker of survival.Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatmentRevealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients.The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up.Molecular and chromosomal alterations: new therapies for relapsed acute myeloid leukemia.Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS.Epigenetically induced ectopic expression of UNCX impairs the proliferation and differentiation of myeloid cells.Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up.Opposite activation of the Hedgehog pathway in CD138+ plasma cells and CD138-CD19+ B cells identifies two subgroups of patients with multiple myeloma and different prognosis.Efficacy of Azacitidine in the treatment of adult patients aged 65 years or older with AML.Treatment of Ph+ chronic myeloid leukemia by gamma interferon.Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib.t(8;14)(q11;q32) in acute lymphoid leukemia: description of two cases.Granulocytic sarcomas: clinical, diagnostic and therapeutical aspects.Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysis.Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib.Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia.CD56 antigenic expression in acute myeloid leukemia identifies patients with poor clinical prognosis.A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia.Incidence and significance of cryptic chromosome aberrations detected by fluorescence in situ hybridization in acute myeloid leukemia with normal karyotype.Novel translocations that disrupt the platelet-derived growth factor receptor beta (PDGFRB) gene in BCR-ABL-negative chronic myeloproliferative disorders.A phase II study of alpha-interferon and oral arabinosyl cytosine (YNK01) in chronic myeloid leukemia.Molecular response to imatinib in late chronic-phase chronic myeloid leukemia.Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia.Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome.Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study.Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia.Positron emission tomography with computed tomography-based diagnosis of massive extramedullary progression in a patient with high-risk multiple myeloma.Emergence of clonal chromosomal abnormalities in Philadelphia negative hematopoiesis in chronic myeloid leukemia patients treated with nilotinib after failure of imatinib therapy.Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party.Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy.Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response.
P50
Q33409349-F0ACBFD2-E923-42F1-B57C-82C82A5970CFQ33421005-3BA78707-CB96-40E3-8047-538B1CE1C122Q33728189-05A60A65-5227-4A81-B61F-06B7C2DB50C4Q33760754-92657E20-3B9A-41CC-BF7C-D837041F2EE2Q34032263-0C72658E-7385-43AF-BEBD-90B706572A5CQ34112282-AAB4F7C5-E552-4BB7-91F0-34F706D30C5EQ34401962-553C77FF-B8B6-4834-AB44-DF63EAB2616DQ35067505-7E3A26C1-3819-435A-8F19-9607FE40843EQ35143847-E44F7A5E-90C7-407E-8C02-B5F672725047Q36288815-D3337333-2842-4EFB-8ECB-EB17425B0138Q36544560-3640DCBA-973A-4BB8-91E7-4DA5D04D6456Q37082725-02769625-CE81-4C29-ABD7-87F2223141CBQ37183513-0F5FDDBE-5E25-41DA-BBE3-B6BCAD11EB2DQ37341297-61771ED0-52CD-43D6-B03A-A592AC870FE8Q38374992-985E495C-8BD3-4947-B36D-9B6FEEBB7551Q38386719-84B583BA-D04A-42D2-8263-197B6D3BAA08Q38778519-FE6C9A97-5162-48CE-A9DE-A2DE87833336Q38797003-E590D35A-CE07-4D3C-805C-930366015558Q40773835-85B7CD28-963C-4F88-A882-6B836DE9F671Q40821920-ADD9D750-3B86-45CF-AA1B-E68EB4544B0EQ40913048-F92FF5B5-715C-4E23-82A3-17E7D231E912Q41475517-1A4EC39D-BF1A-415F-B7E8-1B377112749DQ43075393-D9E80F3D-DF90-4A4D-A11B-6F44AFC3AB88Q43255365-390AC47D-BF9D-4410-90A6-C5E4E588253EQ43262982-3F4CD000-8E59-4FFF-82D6-94948F24E4C0Q43692566-5271A122-DB49-4A69-BF21-A4FB0E0F4E96Q43893057-C4D57A6A-202B-4349-A352-A10603A5CAA6Q44117868-F0AF322E-F694-433D-8DF0-0BBE878B7F11Q44287656-536D9F79-C9B2-4D80-A220-A900D2353546Q44368779-4C9FCE35-18D7-4705-A507-B920291EABDFQ44673850-E00DA507-DBA6-4110-A7F0-69D946993EB7Q44680313-1854B794-1E22-4407-93DF-66D6A601615EQ44753123-CB25791B-1B73-45C1-BE31-10E338F61F97Q44912433-162C25F2-2B20-46C3-BBDA-91E7BB7D87DEQ45023456-329359CA-798E-4C4E-9231-14B98709F5A7Q45961614-2D0DBDBB-528E-4C29-A86C-360A7679317EQ45969980-DC5C67FE-8C4A-4553-ACA7-843C67D189FFQ46124555-8401F212-BFA9-4045-8F6B-7EA4288D2DE4Q46126059-77C27C53-9988-4280-9912-8F5D4FBCE36CQ46136039-B0EF617C-0011-4CB7-A294-EB738BE226AE
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Nicoletta Testoni
@ast
Nicoletta Testoni
@en
Nicoletta Testoni
@es
Nicoletta Testoni
@nl
type
label
Nicoletta Testoni
@ast
Nicoletta Testoni
@en
Nicoletta Testoni
@es
Nicoletta Testoni
@nl
prefLabel
Nicoletta Testoni
@ast
Nicoletta Testoni
@en
Nicoletta Testoni
@es
Nicoletta Testoni
@nl
P106
P1153
7005746998
P31
P496
0000-0001-6785-5132